Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
Abstract
A method of inducing either a T H 1 polarised immune response, a T H 2 polarised immune response or a combined T H 1 and T H 2 response to an antigen and associated vaccine formulations are disclosed. A method is provided for inducing a polarised T H 1 response by parenteral administration of microparticles sized such that at least 50% of the microparticles are less than 5 μm, the microparticles containing antigen entrapped or encapsulated by a biodegradable polymer. Additionally, a method is provided for inducing a polarised T H 2 response by parenteral administration of nanoparticles sized such that at least 50% of the nanoparticles are less than 600 nm, the nanoparticles containing antigen entrapped or encapsulated by a biodegradable polymer. Vaccine formulations containing the B. pertussis antigens PTd, FHA or a combination of PTd and FHA are provided.
Claims
exact text as granted — not AI-modified1 . A method of inducing a T H 2 polarised immune response to an antigen, comprising parenterally administering to a subject nanoparticles sized such that at least 50% of the nanoparticles are less than 600 nm, the nanoparticles comprising the antigen entrapped or encapsulated by a biodegradable polymer.
2 . The method of claim 1 , wherein the nanoparticles are sized such that at least 50% of the nanoparticles are less than 500 nm.
3 . The method of claim 1 , wherein the biodegradable polymer comprises a copolymer of lactic acid and glycolic acid or enantiomers thereof.
4 . The method of claim 1 , wherein the nanoparticles are formed using a coacervation method.
5 . The method of claim 1 , wherein the antigen comprises a B. pertussis antigen.
6 . The method of claim 1 , wherein the parenteral administration is selected from the group consisting of intraperitoneal administration, subcutaneous administration and intramuscular administration.Join the waitlist — get patent alerts
Track US2008254134A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.